BRPI0507518A - inibidor de hiperplasia vascular da ìntima - Google Patents

inibidor de hiperplasia vascular da ìntima

Info

Publication number
BRPI0507518A
BRPI0507518A BRPI0507518-1A BRPI0507518A BRPI0507518A BR PI0507518 A BRPI0507518 A BR PI0507518A BR PI0507518 A BRPI0507518 A BR PI0507518A BR PI0507518 A BRPI0507518 A BR PI0507518A
Authority
BR
Brazil
Prior art keywords
inhibitor
hydrogen atom
hyperplasia inhibitor
group
vascular hyperplasia
Prior art date
Application number
BRPI0507518-1A
Other languages
English (en)
Inventor
Hiroshi Nishiyama
Norimasa Shudo
Nobutomo Tsuruzoe
Original Assignee
Nissan Chemical Ind Ltd
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Ind Ltd
Publication of BRPI0507518A publication Critical patent/BRPI0507518A/pt
Publication of BRPI0507518A8 publication Critical patent/BRPI0507518A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDOR DA HIPERPLASIA VASCULAR DA ìNTIMA". A presente invenção refere-se a fornecer um inibidor de hiperplasia daíntima útil para a prevenção da restenose após a angioplastia coronariana transluminal percutânea (PTCA) ou a colocação de stent vascular ou o tratamento do seu progresso. Um inibidor da hiperplasia da íntima contendo um composto 3(2H)-piridazinona representado pela fórmula (I): na qual cada um dos R¬ 1¬, R¬ 2¬ e R¬ 3¬ é independentemente um átomo de hidrogênio ou um grupo alquila-C~ 1~-~ 6~, X é um átomo de halogênio, um grupo ciano ou um átomo de hidrogênio, Y é um átomo de halogênio, trifluorometila ou um átomode hidrogênio e A é um alquileno-C~ 1~-~ 8~ que pode ser substituído com um grupo hidroxila ou um sal famacologicamente aceitável do mesmo.
BRPI0507518A 2004-02-09 2005-02-02 Inibidor de hiperplasia vascular da íntima BRPI0507518A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004032551 2004-02-09
PCT/JP2005/001518 WO2005074938A1 (ja) 2004-02-09 2005-02-02 血管内膜肥厚抑制薬

Publications (2)

Publication Number Publication Date
BRPI0507518A true BRPI0507518A (pt) 2007-07-03
BRPI0507518A8 BRPI0507518A8 (pt) 2015-12-01

Family

ID=34836093

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507518A BRPI0507518A8 (pt) 2004-02-09 2005-02-02 Inibidor de hiperplasia vascular da íntima

Country Status (13)

Country Link
US (2) US20070161642A1 (pt)
EP (1) EP1714654A4 (pt)
JP (1) JP4783152B2 (pt)
KR (1) KR20070029133A (pt)
CN (1) CN100506230C (pt)
AU (1) AU2005210326B2 (pt)
BR (1) BRPI0507518A8 (pt)
CA (1) CA2553915C (pt)
HK (1) HK1098377A1 (pt)
IL (1) IL176795A (pt)
RU (1) RU2339381C2 (pt)
TW (1) TWI357409B (pt)
WO (1) WO2005074938A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
MX2009008531A (es) * 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
FR2948939B1 (fr) * 2009-08-05 2013-03-22 Pf Medicament Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053863C (en) * 1990-04-25 1996-10-29 Keizo Tanikawa Pyridazinone derivatives
JP3666042B2 (ja) * 1994-01-25 2005-06-29 日産化学工業株式会社 ピリダジノン誘導体
AU1466395A (en) * 1994-01-25 1995-08-08 Nissan Chemical Industries Ltd. Pyridazinone derivative
TW338037B (en) * 1995-10-05 1998-08-11 Otsuka Pharma Co Ltd Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition
JP2964029B2 (ja) * 1995-10-05 1999-10-18 大塚製薬株式会社 カルボスチリル誘導体
US6284758B1 (en) * 1997-08-28 2001-09-04 Welfide Corporation Angiogenesis promoters and angiogenesis potentiators
JP4366865B2 (ja) * 1998-09-01 2009-11-18 日産化学工業株式会社 脊柱管狭窄症治療剤
CN1163230C (zh) * 1998-12-07 2004-08-25 日产化学工业株式会社 勃起功能障碍治疗剂
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Also Published As

Publication number Publication date
RU2006132389A (ru) 2008-03-20
EP1714654A4 (en) 2011-02-16
BRPI0507518A8 (pt) 2015-12-01
TWI357409B (en) 2012-02-01
KR20070029133A (ko) 2007-03-13
EP1714654A1 (en) 2006-10-25
HK1098377A1 (en) 2007-07-20
JP4783152B2 (ja) 2011-09-28
IL176795A (en) 2013-01-31
AU2005210326B2 (en) 2009-10-22
JPWO2005074938A1 (ja) 2007-09-13
US20090155187A1 (en) 2009-06-18
TW200530218A (en) 2005-09-16
IL176795A0 (en) 2006-10-31
CA2553915C (en) 2010-06-01
CA2553915A1 (en) 2005-08-18
CN1905882A (zh) 2007-01-31
US20070161642A1 (en) 2007-07-12
AU2005210326A1 (en) 2005-08-18
WO2005074938A1 (ja) 2005-08-18
CN100506230C (zh) 2009-07-01
RU2339381C2 (ru) 2008-11-27

Similar Documents

Publication Publication Date Title
Costas et al. New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
CA2557576A1 (en) Novel benzothiazepine and benzothiepine compounds
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BRPI0507518A (pt) inibidor de hiperplasia vascular da ìntima
DE60013130D1 (de) Konjugate von ascorbinsäure und phytosterolen oder phytostanolen und ihre verwendung zur behandlung von gefässkrankheiten
DE602005005240D1 (de) 4'-C-substituierte 2-Haloadenosinderivate
BR0316386A (pt) Benzoxazin-3-onas e seus derivados como inibidores de p13k
BRPI0512790A (pt) derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
EP1180518A4 (en) 5-PYRIDYLE-1,3-AZOLE COMPOUNDS, THEIR MANUFACTURING PROCESS AND THEIR USE
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
UY27654A1 (es) Derivados de dihidrobenzodiazepin-ona iii
NO20072688L (no) Aminpyridinderivat med aurora A-selektiv inhiberende virkning
DE60228316D1 (en) Xanthinoxidaseinhibitoren
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
WO2006104870A3 (en) Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
PT1757610E (pt) Derivado de pirimidina condensada e inibidor da xantina oxidase
ATE440096T1 (de) Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
BRPI0417345A (pt) compostos inibidores de quìnase baseados em azola, composições e seus usos
NO974280L (no) Intima hypertrofiinhibitorer
BR0211203A (pt) Acilsemicarbazidas como inibidores de cinase dependente de ciclina úteis como agentes anti-câncer e anti-proliferativos
BR0316785A (pt) Derivados de 4-pirimidona-3-substituìdos
DE69200757D1 (de) Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption.
WO2001066560A3 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NISSAN CHEMICAL INDUSTRIES LTD (JP)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]